Table 2. Summary of clinical trials evaluating cetuximab.

Disease	Cytotoxic agents	Trial design	Results
Colorectal cancer	Irinotecan	Phase II trial in patients progressing on irinotecan	Partial response 22.5%Stable disease 7%
		Phase III trial in patients progressing on irinotecan comparing cetuximab to the combination	Response rate (23 vs 11%), stable disease (55.5% vs 32%), and TTP (4.1 vs 1.5 months) significantly improved by the combination
SCCHN	Cisplatin	Phase II trial in patients progressing on cisplatin	Response rate 11%
		Phase III trial in patients progressing on cisplatin comparing cetuximab to the combination	Significant improvement in response rate but not in survival
Pancreatic cancer	Gemcitabine	Phase II trial in previously untreated patients	Overall response rate 51%. Median TTP 12 weeks
NSCLC	Cisplatin/vinorelbine	Randomised trial in the first line setting	Response rate 50% in the cetuximab/chemotherapy arm vs 29% in the chemotherapy only arm